In the last trading session, 2.39 million Xilio Therapeutics Inc (NASDAQ:XLO) shares changed hands as the company’s beta touched -0.31. With the company’s per share price at $0.94 changed hands at $0.01 or 0.99% during last session, the market valuation stood at $42.97M. XLO’s last price was a discount, traded about -105.32% off its 52-week high of $1.93. The share price had its 52-week low at $0.53, which suggests the last value was 43.62% up since then.
Analysts gave the Xilio Therapeutics Inc (XLO) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.33. If we narrow down to specifics, the data shows that 0 out of 1 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended XLO as a Hold, 1 felt it is a Buy and 0 rated the stock as Underweight. Xilio Therapeutics Inc’s EPS for the current quarter is expected to be -0.22.
Xilio Therapeutics Inc (NASDAQ:XLO) trade information
Instantly XLO was in green as seen at the end of in last trading. With action -17.61%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -1.65%, with the 5-day performance at -17.61% in the red. However, in the 30-day time frame, Xilio Therapeutics Inc (NASDAQ:XLO) is 13.20% up.
The consensus price target for the stock as assigned by Wall Street analysts is 7, meaning bulls need an upside of 86.57% from its current market value. According to analyst projections, XLO’s forecast low is 7 with 7 as the target high. To hit the forecast high, the stock’s price needs a -644.68% plunge from its current level, while the stock would need to soar -644.68% for it to hit the projected low.
Consensus estimates given by 2 financial analysts project the company’s revenue in the current quarter to hit an average of 3.3M. 2 analysts are of the opinion that Xilio Therapeutics Inc’s revenue for the current quarter will be 23.9M. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 0.00%. The estimates for the next quarter sales put growth at 0.00%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -44.91%. The 2025 estimates are for Xilio Therapeutics Inc earnings to increase by 59.04%, but the outlook for the next 5-year period is at 39.65% per year.
XLO Dividends
Xilio Therapeutics Inc is expected to release its next quarterly earnings report in March.
ROCK SPRINGS CAPITAL MANAGEMENT LP holds the second largest percentage of outstanding shares, with 10.7595% or 3.0 million shares worth $2.85 million as of 2024-06-30.
Among Mutual Funds, the top two as of Sep 30, 2024 were Vanguard Total Stock Market Index Fund and Fidelity Extended Market Index Fund . With 739.56 shares estimated at $0.69 million under it, the former controlled 1.68% of total outstanding shares. On the other hand, Fidelity Extended Market Index Fund held about 0.41% of the shares, roughly 180.18 shares worth around $0.17 million.
